Did You Know...
...that in the early 1940s GE engineer James Wright was charged with a task of utmost importance to the war effort: develop a cheap substitute for rubber that could be used to produce tires, gas masks and a whole host of military gear. Wright tackled the task diligently -- and wound up inventing Silly Putty.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8101205 | Controlled release composition The invention relates to the field of pharmacology. More specific, the invention relates to a controlled release composition. This invention is related to a controlled release composition comprising a cross-linked gelatin and at least one therapeutic protein ... | 01/24/2012 |
| 7985422 | Dosage form A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to ... | 07/26/2011 |
| 7976871 | Modified release composition of highly soluble drugs A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents. Present invention can optionally comprise additionally another active ingre... | 07/12/2011 |
| 7910132 | Pharmaceutical composition for the treatment of acute disorders A pharmaceutical composition for the treatment of acute disorders is described. The composition comprises an essentially water-free, ordered mixture of at least one pharmaceutically active agent in the form of microparticles which are adhered to the surfaces of carr... | 03/22/2011 |
| 7862834 | Pharmaceutical formulation comprising a water-insoluble active agent A method of preparing a pharmaceutical formulation comprises providing a solution comprising a first solvent, a second solvent, an active agent, and an excipient. The second solvent is less polar than the first solvent and the excipient is more soluble in water than... | 01/04/2011 |
| 7838033 | Composition for rapid disintegrating tablet in oral cavity The present invention provides rapid disintegrating tablets in oral cavity having a shortened disintegration time in oral cavity as well as a sufficient hardness with compared to rapid disintegrating tablets of the prior art. The above objective is solved by ... | 11/23/2010 |
| 7718192 | Tamper-resistant oral opioid agonist formulations Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact. ... | 05/18/2010 |
| 7704528 | Binder composition and method for processing poorly compressible drugs into tablets of predetermined hardness and friability Tablets of a poorly compressible drug are made by direct compression using a binder composition which is a polymer, preferably a copolymer of polyvinylpyrrolidone (PVP) and vinyl acetate (VA), having a defined glass transition temperature (Tg), admixed with a plasti... | 04/27/2010 |
| 7695735 | Fast disintegrating tablet The invention concerns an improved multiparticulate tablet disintegrating in the mouth in contact with saliva in less than 40 seconds. The invention is characterized in that it is based on particles of coated active principle, said particles having intrinsic compres... | 04/13/2010 |
| 7442387 | Pharmaceutical composition for controlled release of active substances and manufacturing method thereof The present invention pertains to a sized product, which contains a drug, polyethylene oxide with a molecular weight of 2,000,000 or higher, and a specific size controlling agent for polyethylene oxide (substance with the appropriate plasticity and binding force) an... | 10/28/2008 |
| 7438930 | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations The invention is directed to oral modified/controlled release drug formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate r... | 10/21/2008 |
| 7431943 | Controlled release and taste masking oral pharmaceutical compositions Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrop... | 10/07/2008 |
| 7427413 | Stable shaped particles of crystalline organic compounds The present invention provides storage stable, shaped particles of allotropic organic compounds. The particles of the present invention can be shaped according to the desired application. Preferred shapes of such particles are microspheres, particularly those having... | 09/23/2008 |
| 7422758 | Sustained release vitamin composition A therapeutic formulation in the form of a beadlet, suitable for oral administration and adapted to provide immediate and sustained release of therapeutic material. Each beadlet comprises an extruded-spheronized inner core containing at least one medicament e.g. a s... | 09/09/2008 |
| 7419686 | Opioid agonist/antagonist combinations The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide ... | 09/02/2008 |
| 7413750 | Process for producing solid oral dosage forms with sustained release of active ingredient The present invention relates to a process for producing solid oral dosage forms with sustained release of active ingredient, comprising at least one active ingredient, a preformulated mixture of polyvinyl acetate and polyvinylpyrrolidone, where appropriate, water-s... | 08/19/2008 |
| 7410651 | Controlled release and taste masking oral pharmaceutical composition Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrop... | 08/12/2008 |
| 7410652 | Controlled release and taste masking oral pharmaceutical composition Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrop... | 08/12/2008 |
| 7387791 | Liposome drug delivery This invention comprises pharmaceutical compositions for administering a biologically active compound to an animal. Particularly provided are proliposomal compositions that are advantageously used to deliver biologically active compounds to the gastrointestinal trac... | 06/17/2008 |
| 7384653 | Oral dosage form comprising a therapeutic agent and an adverse-effect agent The present invention provides an oral dosage form comprising a first composition and a second composition. The first composition comprises an effective amount of a therapeutic agent and the second composition comprises an effective amount of an adverse-effect agent... | 06/10/2008 |
| 7335380 | Amlodipine free base Amlodipine free base can be formulated into a convenient oral dosage form, especially a tablet, without excessive stickiness or tablet punch residue. The amlodipine free base can be crystalline Form I or a novel Form II. Methods of making and using the amlodipine fr... | 02/26/2008 |
| 7332183 | Multilayer dosage forms containing NSAIDs and triptans The present invention is directed to multilayer pharmaceutical tablets in which an NSAID and a triptan are present in separate and distinct layers. The layers are in a side-by-side configuration, which allows the dissolution of triptan and NSAID to occur independent... | 02/19/2008 |
| 7320802 | Methods of treatment using nanoparticulate fenofibrate compositions The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm. ... | 01/22/2008 |
| 7316821 | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer A stabilized solid controlled release dosage form having a coating derived from an aqueous dispersion of ethylcellulose is obtained by overcoating a substrate including a therapeutically active with an aqueous dispersion of ethylcellulose and then curing the coated ... | 01/08/2008 |
| 7314640 | Formulation and process for drug loaded cores The present invention relates to a controlled release pellet of metoprolol and its pharmaceutically acceptable salts that uses a water soluble or a water swellable inert starting seed or core. ... | 01/01/2008 |
| 7303765 | Ultrafine-L-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same L-carnitine which has a particle size such that it substantially passes through a 100 USBS mesh sieve exhibits an increased bioavailability, a decreased hygroscopicity, and may be conveniently formulated with oil-based materials. ... | 12/04/2007 |
| 7300919 | Pulmonary delivery of active fragments of parathyroid hormone Systemic delivery of parathyroid hormone to a mammalian host is accomplished by inhalation through the mouth of a dispersion of an N-terminal fragment of PTH. It has been found that such respiratory delivery of the PTH fragment provides a pulsatile concentration pro... | 11/27/2007 |
| 7282221 | Antiviral product, use and formulation thereof An antiviral product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antiviral product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosag... | 10/16/2007 |
| 7282217 | Rapidly disintegrable tablets The invention provides a rapidly disintegrating tablet comprising an active ingredient, a water soluble, directly compressible carbohydrate, and a water soluble, directly compressible filler. Also provided is a method of producing a rapidly disintegrating tablet, wh... | 10/16/2007 |
| 7276253 | Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof The invention relates to a stable medicament for oral administration which comprises (a) a core which contains an active ingredient selected from Omeprazole, Lansoprazole and Pantoprazole, together with customary pharmaceutical adjuvants, (... | 10/02/2007 |
| 7276249 | Nanoparticulate fibrate formulations The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm. ... | 10/02/2007 |
| 7276250 | Sustained release formulations of oxymorphone Sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of... | 10/02/2007 |
| 7276252 | Method and form of a drug delivery device, such as encapsulating a toxic core within a non-toxic region in an oral dosage form A drug delivery device such as an oral dosage form (ODF) with a toxic or potent core encapsulated by a non-toxic region. The non-toxic region may be a region including multiple layers, coatings, shells, and combinations thereof, which provides protection to and isol... | 10/02/2007 |
| 7273624 | Stable dosage forms containing ubiquinones The invention relates to stable solid dosage forms for peroral administration containing, in addition to an ubiquinone, at least one thermoplastically processible matrix-forming auxiliary agent. ... | 09/25/2007 |
| 7270831 | Orally administrable opioid formulations having extended duration of effect Sustained release oral solid dosage forms of opioid analgesics are provided as multiparticulate systems which are bioavailable and which provide effective blood levels of the opioid analgesic for at least about 24 hours. A unit dose of the opioid analgesic contains ... | 09/18/2007 |
| 7265156 | Medicinal association of a biguanine and a carrier, for example metformin and arginine The present invention relates to a compound of formula III, method of making the same and its use in the treatment of diabetes. ... | 09/04/2007 |
| 7258872 | Chromone enteric release formulation Orally administered chromones have been found to be effective in the treatment of allergic conditions such as asthma, general food allergies, ulcerative colitis, atopic eczema, chronic urticaria, and irritable bowel syndrome if it is presented such that the respecti... | 08/21/2007 |
| 7255876 | Composition comprises sustained-release fine particles and manufacturing method thereof The present invention relates to a composition comprising sustained-release fine particles, characterized in that it contains sustained-release fine particles that can be used in quick-disintegrating tablets in the buccal cavity, one or more fillers selected from th... | 08/14/2007 |
| 7247318 | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations The invention is directed to oral modified/controlled release drug formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate r... | 07/24/2007 |
| 7238372 | Methods for inhibiting tumor cell proliferation The subject invention concerns methods for inhibition of STAT biological functions using platinum complexes. ... | 07/03/2007 |
